|Bid||83.750 x 1100|
|Ask||83.830 x 800|
|Day's range||83.288 - 85.470|
|52-week range||51.050 - 135.590|
|PE ratio (TTM)||N/A|
|Earnings date||30 Jul 2018 - 3 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||106.69|
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.
Viking Therapeutics’ (VKTX) stock price rose ~101% on May 31 following the successful trial results of Madrigal Pharmaceuticals’ (MDGL) NASH drug. Madrigal Pharmaceuticals’ drug has a similar mechanism of action as Viking Pharmaceuticals’ NASH drug. In this part, we’ll discuss Wall Street analysts’ recommendations for Viking Therapeutics stock in the next 12 months.
Madrigal Pharmaceuticals, the biotech company based in West Conshohocken, Pennsylvania, saw its share price rise more than 150% today after announcing a successful completion of its Phase II clinical trial to reduce nonalcoholic steatohepatitis (NASH). NASH, also known as fatty liver disease, is a disorder related to obesity and is steadily gaining prevalence throughout the developing world.
Madrigal Pharmaceuticals Inc. more than doubled after a study of its new drug for a disease linked to obesity exceeded investor expectations. The results from a mid-stage study of the fatty liver disease known as nonalcoholic steatohepatitis, or NASH, also pushed small-cap peer Viking Therapeutics Inc. higher while shares of Intercept Pharmaceuticals Inc., a drugmaker further along in NASH development, slid. Patients getting Madrigal’s experimental therapy known as MGL-3196 had a two-point reduction in a score that measures disease activity with a liver biopsy.
The race is on to identify the wonder drug that will treat an increasingly common consequence of obesity: the fatty liver disease known as nonalcoholic steatohepatitis, or NASH. Madrigal Pharmaceuticals Inc. is expected to report results from a mid-stage study in NASH by Thursday. The drug developer is racing against peers like Intercept Pharmaceuticals Inc. to get its experimental therapy known as MGL-3196 to the market.
Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.
The New York-based company said it had a loss of $3.22 per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss ...
Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.
Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).
CymaBay launched to a month-high Wednesday after unveiling strong data for a liver disease treatment — to the detriment of Intercept which has struggled with its rival drug.
Intercept Pharmaceuticals (ICPT) spent $265.4 million on operating activities in fiscal 2017 compared with $342.4 million in fiscal 2016. In fiscal 2017, Intercept Pharmaceuticals generated $2.8 million from financing activities, which were mainly from the exercise of options to purchase common stock. On April 5, 2018, Intercept Pharmaceuticals announced pricing of the upsized $250 million public offering of its common stock with a concurrent private placement of 1.5 million of its common shares.
Enanta Pharmaceuticals (ENTA) is a biotechnology company with a chemistry-driven approach. Enanta Pharmaceuticals discovered glecaprevir, a protease inhibitor for the treatment of chronic hepatitis C virus (or HCV). Enanta’s second protease inhibitor under its collaboration with AbbVie is marketed under the tradename Viekera Pak under AbbVie’s initial DAA regimens for the treatment of chronic HCV.
Acorda Therapeutics (ACOR), a biopharmaceutical company, develops therapies for neurological disorders. Of the ten analysts covering Acorda Therapeutics in April 2018, three have recommended “buy,” six have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.8, and their target price is $24.78. Of the 20 analysts covering Intercept Pharmaceuticals (ICPT) in April 2018, ten have recommended “buy” or a higher rating, seven have recommended “hold,” and three have recommended “sell.” The mean rating for the stock is 2.5, and its target price is $110.91.
FibroGen (FGEN) is a biopharmaceutical company involved in the discovery and development of first-in-class therapeutics. The drug is in Phase 3 of development for the treatment of anemia in chronic kidney disease. The company has adopted a global approach to the development and commercialization of its product candidates.
Intercept Pharmaceuticals (ICPT) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of viral, progressive liver diseases utilizing its proprietary bile acid chemistry. Of the 20 analysts covering Intercept Pharmaceuticals in April 2018, ten of them have given the stock a “buy” or higher rating. Seven analysts have given it a “hold,” and three have given it a “sell.” The mean rating for the stock is 2.5 with a target price of $110.91.